HOME / Newsroom /
Canadian Companies Entos Pharmaceuticals and Montrium Partner to Advance Clinical Research

Canadian Companies Entos Pharmaceuticals and Montrium Partner to Advance Clinical Research

MONTREAL, QC and EDMONTON, AB, July 7, 2021 - Montrium, a leader in cloud-based software solutions for life sciences, today announces that Entos Pharmaceuticals (Entos), an innovator in the development of genetic medicine, has implemented eTMF Connect and Quality Connect to power clinical operations and facilitate critical pharmaceutical developments.

Specializing in the creation of next generation genetic therapies using their Fusogenix nucleic acid delivery platform, Entos has been rapidly expanding its team and its product portfolio. With personnel across North America involved in a variety of groundbreaking clinical research projects, Entos recognized the need for a digital, centralized system to access and manage essential clinical trial documentation.

When choosing a software vendor, Entos was impressed by Montrium's convenient solutions, which allowed them to quickly begin optimizing their quality documentation processes. "We liked the off-the-shelf product that Montrium was able to offer," said Kevin James, Quality Coordinator and Business Development Specialist at Entos. He also highlighted the appeal of the comprehensiveness of Montrium's offerings, stating that "Montrium was one of the very few companies that was able to offer both an eTMF platform and a suite of quality support management for documentation and training."

The partnership between Entos and Montrium showcases the immense potential of Canadian businesses in advancing clinical research. Thanks in part to Montrium's software, Entos was able to implement robust quality processes in tandem with their development of a promising COVID-19 vaccine which is now undergoing a phase 1 clinical trial in Halifax, Nova Scotia. "Montrium was able to help us accelerate our quality management documentation systems as we have been rapidly advancing our COVID-19 vaccine program in Canada, stated Kevin James.

"We are proud to be supporting a fellow Canadian company in developing cutting-edge therapies by providing them with the tools to ensure that all necessary trial documentation is easily maintained and that all quality standards are met. We look forward to seeing how eTMF Connect and Quality Connect will continue to help Entos Pharmaceuticals excel in the industry, said Michael Pupil, Head of Sales at Montrium.

About Montrium

Founded in 2005, Montrium is one of the leading providers of cloud-based collaborative content management software to the life sciences industry. With experience in serving over 200 life science customers in 20+ countries, Montrium is committed to delivering an unparalleled customer experience to emerging growth organizations as a true technology partner. Montrium has offices in Montreal, Canada, and Brussels, Belgium.

About Entos Pharmaceuticals, Inc.

Entos develops next generation nucleic acid-based therapies using its proprietary Fusogenix drug delivery system. Fusogenix is a proteo-lipid vehicle (PLV) formulation that uses a novel mechanism of action to deliver molecules, intact and unmodified, directly into the cytosol of target cells. The technology applies a wide range of therapeutic types, including gene therapy, mRNA, miRNA, RNAi, CRISPR, and small molecule drugs. For more information, visit http://www.entospharma.com

Media Contacts:

Entos Pharmaceuticals

John D. Lewis, Ph.D.

CEO, Entos Pharmaceuticals, Inc.



Oliver Pearce

Head of Growth, Montrium


T: +1 514 .223. 9153 ext. 283 (North America)

T: +32.2.808.30.08 ext. 283 (Europe)